文献速递白血病淋巴瘤造血干细胞移植与细胞治疗

达雷妥尤单抗治疗儿童复发/难治性急性淋巴细胞白血病或淋巴母细胞淋巴瘤:DELPHINUS研究

Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study.
PubMed 文献 · Blood · 2024-01-01

DELPHINUS是一项2期开放标签研究,评估达雷妥尤单抗(16 mg/kg 静脉注射)联合化疗治疗复发/难治性B细胞急性淋巴细胞白血病(ALL)、T细胞ALL及淋巴母细胞淋巴瘤(LL)儿童及年轻患者。B细胞ALL队列未达完全缓解而因无效终止;T细胞ALL儿童、年轻成人及T细胞LL队列的完全缓解率分别为41.7%、60.0%和30.0%,且安全性可控。

要点

  • B细胞ALL患者(n=7)接受达雷妥尤单抗联合化疗后无完全缓解,该队列因无效终止。
  • T细胞ALL儿童、年轻成人及T细胞LL的完全缓解率分别为41.7%、60.0%和30.0%。
  • 达雷妥尤单抗与化疗联合安全性可控,未观察到新的安全性问题。

核心结论

  • 达雷妥尤单抗可与化疗安全联合用于儿童和年轻成人T细胞ALL/LL,并有助于成功桥接至异基因造血干细胞移植。

研究设计与样本

  • 2期开放标签DELPHINUS研究评估达雷妥尤单抗(16 mg/kg 静脉注射)联合化疗。
  • 入组复发/难治性B细胞ALL儿童(n=7,≥2次复发后)、T细胞ALL儿童(n=24)和年轻成人(n=5)以及T细胞LL儿童和年轻成人(n=10,首次复发后)。
  • 主要终点为B细胞ALL队列(第2周期末)和T细胞ALL队列(第1周期末)的完全缓解率。

主要发现

  • B细胞ALL队列7例患者接受达雷妥尤单抗联合化疗后无完全缓解,该队列因无效终止。
  • T细胞ALL儿童、年轻成人及T细胞LL队列第1周期末完全缓解率分别为41.7%、60.0%和30.0%。
  • 任意时间点总缓解率分别为83.3%(完全缓解+计数未完全恢复的完全缓解)、80.0%(完全缓解+计数未完全恢复的完全缓解)和50.0%(完全缓解+部分缓解)。
  • 微小残留病阴性(<0.01%)率分别为45.8%、20.0%和50.0%;24个月无事件生存率分别为36.1%、20.0%和20.0%;24个月总生存率分别为41.3%、25.0%和20.0%;异基因造血干细胞移植率分别为75.0%、60.0%和30.0%。
  • 未观察到达雷妥尤单抗新的安全性问题。

临床怎么用

  • 作者认为达雷妥尤单抗可与化疗安全联合用于儿童和年轻成人T细胞ALL/LL,并有助于成功桥接至异基因造血干细胞移植。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with relapsed/refractory acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) have poor outcomes compared with newly diagnosed, treatment-naïve patients. The phase 2, open-label DELPHINUS study evaluated daratumumab (16 mg/kg IV) plus backbone chemotherapy in children with relapsed/refractory B-cell ALL (n = 7) after ≥2 relapses, and children and young adults with T-cell ALL (children, n = 24; young adults, n = 5) or LL (n = 10) after first relapse. The primary end point was complete response (CR) in the B-cell ALL (end of cycle 2) and T-cell ALL (end of cycle 1) cohorts, after which patients could proceed off study to allogeneic hematopoietic stem cell transplant (HSCT). Seven patients with advanced B-cell ALL received daratumumab with no CRs achieved; this cohort was closed because of futility. For the childhood T-cell ALL, young adult T-cell ALL, and T-cell LL cohorts, the CR (end of cycle 1) rates were 41.7%, 60.0%, and 30.0%, respectively; overall response rates (any time point) were 83.3% (CR + CR with incomplete count recovery [CRi]), 80.0% (CR + CRi), and 50.0% (CR + partial response), respectively; minimal residual disease negativity (<0.01%) rates were 45.8%, 20.0%, and 50.0%, respectively; observed 24-month event-free survival rates were 36.1%, 20.0%, and 20.0%, respectively; observed 24-month overall survival rates were 41.3%, 25.0%, and 20.0%, respectively; and allogeneic HSCT rates were 75.0%, 60.0%, and 30.0%, respectively. No new safety concerns with daratumumab were observed. In conclusion, daratumumab was safely combined with backbone chemotherapy in children and young adults with T-cell ALL/LL and contributed to successful bridging to HSCT. This trial was registered at www.clinicaltrials.gov as NCT03384654.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Bhatla T, Hogan LE, Teachey DT, et al. Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study. Blood. 2024. PMID: 39158071. doi:10.1182/blood.2024024493

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。